Hologic (HOLX) Stock Price, News & Analysis

Company Overview

Hologic, Inc. is a global medical technology company focused on women’s health, diagnostics, and medical imaging. The company develops, manufactures, and supplies a broad portfolio of products designed to improve clinical outcomes and enhance efficiency in healthcare settings. Its principal offerings include mammography systems, minimally invasive surgical devices for gynecologic applications, diagnostic tests for infectious diseases and oncology, and bone densitometry systems for skeletal health assessment.

Founded in 1985, Hologic has grown through strategic research and development initiatives as well as targeted acquisitions, such as the purchase of Cytyc Corporation and Gen-Probe. These transactions expanded its capabilities in cervical cancer screening, molecular diagnostics, and tissue management solutions. Today, Hologic serves customers in more than 100 countries, with a strong presence in North America, Europe, Asia-Pacific, and Latin America. The company’s global distribution network includes direct sales forces, distributors, and service centers, enabling it to support healthcare providers in hospitals, diagnostic laboratories, imaging centers, and physician offices.

Hologic places a strong emphasis on innovation, investing in advanced imaging technologies such as 3D mammography and molecular assays designed to deliver faster, more accurate results. Its R&D efforts align with emerging healthcare trends, including personalized medicine and point-of-care testing. Under the leadership of President and Chief Executive Officer Stephen P. MacMillan, Hologic continues to expand its pipeline of novel products and to pursue strategic partnerships that enhance its diagnostic and therapeutic offerings. The company’s commitment to women’s health extends beyond product development, encompassing educational programs, community outreach, and collaborative research endeavors aimed at reducing the global burden of disease.

Key Stats

• Today's Range: $64.49 to $65.30
• 50-Day Range: $52.73 to $65.33
• 52-Week Range: $51.90 to $84.67
• Volume: 1.23 million shs
• Average Volume: 2.37 million shs
• Market Capitalization: $14.43 billion
• P/E Ratio: 27.31
• Dividend Yield: N/A
• Price Target: $77.42
• Consensus Rating: Hold

Hologic Stock Analysis - MarketRank™

Hologic scored higher than 97% of companies evaluated by MarketBeat, and ranked 130th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Hologic has received a consensus rating of Hold. The company's average rating score is 2.41, and is based on 5 buy ratings, 11 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Hologic has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 7.94%

Earnings Growth

Earnings for Hologic are expected to grow by 7.94% in the coming year, from $4.28 to $4.62 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Hologic is 27.31, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.54.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hologic is 27.31, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.47.

Price to Earnings Growth Ratio

Hologic has a PEG Ratio of 2.39. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Hologic has a P/B Ratio of 2.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.28% of the float of Hologic has been sold short.

Short Interest Ratio / Days to Cover

Hologic has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hologic has recently decreased by 1.57%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hologic does not currently pay a dividend.

Dividend Growth

Hologic does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.51

Percentage of Shares Shorted

2.28% of the float of Hologic has been sold short.

Short Interest Ratio / Days to Cover

Hologic has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hologic has recently decreased by 1.57%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.30

News Sentiment

Hologic has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Hologic this week, compared to 13 articles on an average week.

Search Interest

5 people have searched for HOLX on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Hologic insiders have bought more of their company's stock than they have sold. Specifically, they have bought $300,782.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 1.88% of the stock of Hologic is held by insiders.

Percentage Held by Institutions

94.73% of the stock of Hologic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HOLX Stock Analysis - Frequently Asked Questions

How have HOLX shares performed this year?

Hologic's stock was trading at $72.09 on January 1st, 2025. Since then, HOLX shares have decreased by 10.2% and is now trading at $64.7350.

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) posted its earnings results on Thursday, May, 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic's revenue for the quarter was down 1.2% compared to the same quarter last year.
Read the conference call transcript.

Does Hologic have any subsidiaries?

The following companies are subsidiaries of Hologic: Bolder Surgical, Mobidiag Oy, Diagenode SA, Biotheranostics Inc, Somatex Medical Technologies GmbH, Acessa Health, Health Beacons Inc, and others.

How do I buy shares of Hologic?

Shares of HOLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Hologic own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Hologic investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), DiamondRock Hospitality (DRH), The RMR Group (RMR), AU Optronics (AUOTY) and Voyager Therapeutics (VYGR).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 7/04/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:HOLX
• CIK: 859737
• Web: www.hologic.com
• Phone: (508) 263-2900
• Fax: 781-890-8031
• Employees: 7,063
• Year Founded: 1985

Price Target and Rating

• Average Stock Price Target: $77.42
• High Stock Price Target: $94.00
• Low Stock Price Target: $62.00
• Potential Upside/Downside: +19.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.41
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.37
• Trailing P/E Ratio: 27.31
• Forward P/E Ratio: 15.13
• P/E Growth: 2.39
• Net Income: $789.50 million
• Net Margins: 13.83%
• Pretax Margin: 16.92%
• Return on Equity: 19.71%
• Return on Assets: 10.87%

Debt

• Debt-to-Equity Ratio: 0.54
• Current Ratio: 3.24
• Quick Ratio: 2.52

Sales & Book Value

• Annual Sales: $4.03 billion
• Price / Sales: 3.58
• Cash Flow: $5.45 per share
• Price / Cash Flow: 11.87
• Book Value: $22.09 per share
• Price / Book: 2.93

Miscellaneous

• Outstanding Shares: 222,850,000
• Free Float: 218,656,000
• Market Cap: $14.43 billion
• Optionable: Optionable
• Beta: 0.55